Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics (Nasdaq: DMAC) reported second quarter 2026 results and key clinical progress for lead candidate DM199 in preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke (AIS). Cash, cash equivalents and short‑term investments were $43.5 million at June 30, 2026, which the company expects will fund operations through 2027.
In late‑onset preeclampsia Phase 2 Part 1a, DM199 produced statistically significant, sustained blood pressure reductions, including a mean 29.1 mmHg systolic and 17.0 mmHg diastolic decrease at five minutes post‑infusion in the highest‑dose cohorts (n=15). Enrollment of the first six‑patient cohort in the early‑onset FGR Phase 2 study is complete, and a KOL call with topline data is planned for September.
For AIS, the ReMEDy2 Phase 2/3 trial has surpassed 85% of the 200 participants needed for a prespecified interim analysis, expected in early 2027. R&D expenses rose to $8.2 million in Q2 2026, contributing to a quarterly net loss of $10.1 million.
DiaMedica Therapeutics (Nasdaq: DMAC) plans to release its second quarter 2026 financial results after market close on Monday, August 10, 2026. The company will host a live conference call and webcast on Tuesday, August 11, 2026 at 8:00 AM EDT / 7:00 AM CDT to discuss the results and provide a business update.
Investors can access the call via dial-in at (646) 357-8766 using Conference ID 2224408, or through a webcast at https://app.webinar.net/d01wEPk9peA. A webcast replay will be available on DiaMedica’s website for 12 months, and a telephonic replay will be accessible until August 18, 2026 at (800) 770-2030 with passcode 2224408#.
DiaMedica Therapeutics (Nasdaq: DMAC) granted stock options to purchase an aggregate of 160,000 common shares on July 15, 2026 to a newly hired non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
According to DiaMedica, the options were issued under its Amended and Restated 2021 Employment Inducement Incentive Plan, have a $7.64 exercise price (the July 15, 2026 closing price), a 10-year term, and vest 25% after one year with the remaining 75% vesting in 12 quarterly installments, subject to continued service.
DiaMedica Therapeutics (Nasdaq: DMAC) reported dosing the first two patients in an investigator-sponsored Phase 2 trial of DM199 for early-onset fetal growth restriction (FGR). The open-label, single-arm study will assess three dose levels in up to 30 patients. DM199 aims to improve maternal uterine blood flow without crossing into fetal circulation. DiaMedica also released a white paper reviewing the scientific basis for DM199 in FGR.
DiaMedica Therapeutics (Nasdaq: DMAC) received written FDA feedback on nonclinical data needed to advance DM199 for preeclampsia. The FDA indicated a prior rat reproductive toxicity study may support a U.S. IND if drug exposure, enzymatic activity, and pharmacologic effect in rats are adequately demonstrated.
DiaMedica will run a new rat pharmacokinetic and activity study, summarize recent data, and submit the package to FDA, while planning to initiate a preeclampsia study in Canada and the UK later in 2026.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharma company focused on preeclampsia, fetal growth restriction and acute ischemic stroke, will present at the Jefferies Global Healthcare Conference 2026 in New York.
The corporate presentation is scheduled for Thursday, June 4, 2026 at 3:45 PM ET.
DiaMedica Therapeutics (Nasdaq: DMAC) reported that its pivotal Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke has reached 75% of the 200-patient enrollment needed to trigger a pre-specified interim analysis.
An independent DSMB will review the first 200 patients before year-end 2026 and may recommend a final sample size between 300 and 728 patients. ReMEDy2 is a randomized, double-blind, placebo-controlled study, with stroke recovery at Day 90 (mRS 0–1) as the primary endpoint. Approximately 70 sites are active across the United States, Canada, the United Kingdom and Europe.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in the 2026 RBC Capital Markets Global Healthcare Conference in New York City. President and CEO Rick Pauls is scheduled for a fireside chat on Tuesday, May 19, 2026, from 4:05–4:30 PM ET, with additional one-on-one investor meetings available.
DiaMedica Therapeutics (NASDAQ: DMAC) reported first quarter 2026 results and clinical updates on May 6, 2026. The company had $51.3 million in cash and short-term investments as of March 31, 2026, and expects runway through 2027. ReMEDy2 AIS trial enrollment surpassed 70%, with an interim analysis planned in 4Q 2026. Multiple preeclampsia (PE) and fetal growth restriction (FGR) investigator-sponsored and Phase 2 programs are active, with several readouts and a UK CTA planned in 2Q 2026.
DiaMedica Therapeutics (Nasdaq: DMAC) will release first quarter 2026 financial results after market close on May 6, 2026, and host a business update conference call on May 7, 2026 at 8:00 AM ET.
Webcast access, dial‑in details, replay instructions through May 14, 2026, and a 12‑month on‑demand webcast availability are provided. DiaMedica focuses on treatments for preeclampsia, fetal growth restriction and acute ischemic stroke; lead candidate DM199 is a recombinant KLK1 therapeutic.